

Prostate Cancer Market Size to Reach USD 24,930.6 Million by 2035 - Epidemiology Report by IMARC Group

The report provides a detailed analysis of the current marketed drugs and late-stage pipeline drugs.


BROOKLYN, NY, UNITED STATES, July 3, 2025 /EINPresswire.com/ -- The prostate cancer market size reached a value of USD 13,049.5 million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 24,930.6 million by 2035, exhibiting a growth rate (CAGR) of 6.06% during 2025-2035.

The prostate cancer market stands as a comprehensive world ecosystem that supports diagnosis, treatment, and management of prostate cancer. This vast sector covers a very broad category of diagnostic tools, methods of treatments, and a strong pharmaceutical pipeline, treating the disease from its initial stages to very advanced stages. It is thus a dynamic market that keeps on evolving with huge progress in precision medicine, immune therapeutics, and therapies aimed at a great degree of specific targeting.

Request to get a PDF Sample Report: <https://www.imarcgroup.com/prostate-cancer-market/requestsampl>

Innovations and Trends Shaping 2025

The prostate cancer market in 2025 is characterized by the latest innovations in both diagnosis and therapies. Diagnostic technologies are constantly improving, making detection more accurate and at an earlier stage. The most important trends involve the enhancement of the precision of PSA tests, including PSA velocity measurements, and applying PSA density calculations to improve diagnostic accuracy. In addition, new imaging modalities like multiparametric MRI and PSMA PET-CT scans are increasingly available, enhancing early detection and disease staging accuracy. Genomic testing and data analytics integration is also



rising in popularity, especially in North America, enhancing precision medicine strategies further. One of the emerging trends is the expanded use of new combination therapies to enhance outcomes and bypass treatment resistance.

Recent advancements involve the approval of new combinations, like talazoparib with enzalutamide, in metastatic castration-resistant prostate cancer (mCRPC) patients with certain mutations, following previously established options such as olaparib and niraparib with abiraterone. Clinical guidelines increasingly suggest combination therapy, usually two or more drugs blocking hormones, and occasionally chemotherapy, since one-drug therapy is often not considered adequate for metastatic disease. Yet one study shows that these guidelines are not consistently used in daily clinical practice. This discrepancy between best practice as established and practice as delivered indicates a vital need for increased education and wider diffusion of new clinical evidence among health practitioners.

The [prostate cancer market report](#) also provides a detailed analysis of the current marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Competitive Landscape

The competitive landscape of the prostate cancer market has been studied in the report with the detailed profiles of the key players operating in the market.

Sanofi-Aventis

Sanofi

Astellas Pharma

Curium Pharma

Curium Pharma

Buy the full Prostate Cancer Market Epidemiology Report:
<https://www.imarcgroup.com/checkout?id=32804&method=809>

7 Major Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Elena Anderson

IMARC Services Private Limited

+1 631-791-1145

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/827958095>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.